News zum Sektor Gesundheit aus Norwegen

 

OSLO, Norway, April 13, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today announced that the U.S. Food and Drug Administration (FDA) has communicated to Photocure that it plans to issue a proposed order to reclassify diagnostic endoscopic light source systems (FDA Product Code OAY)......

Please find attached Nordhealth AS Group consolidated financial statements including auditor's report for 2025. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com Alexander Cram, CFO alexander.cram@nordhealth.com...

Oslo, 9 April 2026: Lytix Biopharma AS (the “Company”) has granted 100,000 share options to primary insider Darlene Deptula-Hicks, a member of the Company's board of directors, under the Company's long-term incentive program, as approved by the extraordinary general meeting on 26 January 2026.   Each option gives the right to acquire one share in the Company at an exercise price of NOK 9.94. The options are granted without consideration, are subject to vesting over a four-year period, and have a term of five years from the grant date.   Please see the attached notification form...

Oslo, 9 April 2026 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has been informed that Glimt Invest AS, a close associate of Terje Bakken, Chairman of the Board and primary insider of the Company, has purchased 182,000 shares in the Company. Jørgen Mann, Chief Executive Officer of the Company, has purchased 50,000 shares in the Company. Johan Fagerli, Chief Financial Officer of the Company, has purchased 30,000 shares in the Company. For further details, please refer to the attached notification forms. This information is subject to the...

Oslo, 9 April 2026 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 250,000 share options to primary insider and CEO of the Company, Jørgen Mann. Each share option gives the right to subscribe for or purchase one share in the Company or to receive a cash payment of a NOK amount for each exercised option equal to the market price of the Company's shares less the exercise price. The Company's board of directors shall, at its sole discretion, decide whether options that have been duly exercised shall be settled by either new shares, treasury...

Oslo, April 8, 2026: In connection with the Annual General Meeting of Zelluna ASA to be held on April 23, 2026, Anders Tuv, Chair of the Board of Directors, has, as of the date of this announcement, received proxy-based voting rights without voting instructions (discretionary proxies) for 2,308,791 shares, representing 8.79% of the total voting rights in the Company....

OSLO, Norway, April 7, 2026 - Lytix Biopharma AS (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced the appointment of Renée Christine Amundsen as Chief Operating Officer (COO), effective immediately. Her appointment comes at a pivotal point as the Company continues to advance its clinical pipeline and sharpen its operational focus for the next stage of growth. Amundsen brings more than 20 years of global leadership experience across the pharmaceutical and life sciences industries. She has led teams and...

Reference is made to the stock exchange release from earlier today, 1 April 2026 regarding new long-term financing, including agreements with shareholders who have provided guarantees for the new financing. The following companies closely related to primary insiders are a part of the shareholders which have provided guarantees for the new financing: · Ronja Capital AS, a company closely related to Board Member Tore Tønseth, NOK 10,0 million · Vartdal Holding AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,5 million · Brødrene Vartdal AS, a company closely...

Arctic Bioscience has secured new long-term financing through a bank loan of NOK 15 million. Together with previously disclosed increase in credit facility of NOK 8 million from December 2025, the company has increased available liquidity by a total of NOK 23 million. The new loan and the increased credit facility are secured through a growth guarantee from Innovation Norway of NOK 6 million and through guarantees from various shareholders of a total of NOK 18 million. Regarding guarantees from shareholders: Agreements have been entered into with shareholders who have provided...

Helsinki, Finland, 31 March 2026: A maximum of 7,217,260 performance-based options linked to the Company's shares under an incentive scheme (the "Options"), were granted to members of the Company's executive management and key employees, on 30 September 2025. The board of Nordhealth AS (the "Company") has today approved to amend the strike price of all 7,217,260 of the granted options, from NOK 35.20 to NOK 30.00, under the following conditions: · The start of the time-based vesting of the Options is reset to 31st March 2026, and the Options still vest quarterly over 4 years. ·...

The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2025, and HBC has today published the Annual Report and Sustainability Report for 2025. In October 2025, the Company announced a successful placing of new ordinary shares with gross proceeds of NOK 158 million. As of the date of this Annual report, the Company has yet to receive all share deposits and has therefore not completed the transaction. The primary cause of the delay is stated to be of a technical and legal nature relating to the main investor who has repeatedly expressed its intention to swiftly complete the transaction. The Board therefore expects the transaction to be completed in Q2 2026. The proceeds of the transaction will materially strengthen the Company's balance sheet and support ongoing growth momentum....

Helsinki, Finland, 27 March 2026: A close associate of Cezary Cerekwicki, a primary insider of Nordhealth AS (the "Company"), has been granted 3,850 class A shares in the Company in accordance with the Company's performance share plan. Please refer to the attached notification of trading for further details. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com  Alexander Cram, CFO alexander.cram@nordhealth.com  This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian...

Oslo, Norway, 27 March 2026 - Anders Tuv, Managing Director in Radforsk Invest, and Chairperson and co-founder of Zelluna ASA (Zelluna), has today entered into an agreement with Radforsk Investeringsstiftelse (Radforsk) pursuant to which Mr. Tuv has been granted options (the Options) to acquire up to 200,000 shares held by Radforsk in Zelluna....

Oslo, Norway – 26 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, invites investors, analysts and other stakeholders to attend its Capital Markets Update on 14 April 2026 (11:30–13:00 CET). At the event the company will present progress on its TCR-NK off-the-shelf cell therapy platform and ongoing clinical activities, including perspectives on early clinical data and recent developments in the cell therapy field....

Helsinki, Finland, 26 March 2026: Charles MacBain, CEO and a primary insider of Nordhealth AS (the "Company"), has today entered into a derivative contract with his close associates, linked to shares in the Company. The derivatives are linked 1:1 with the said shares. Please refer to the attached notifications of trading for further details. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Alexander Cram, CFO alexander.cram@nordhealth.com +32 470 69 30 20 This information is subject to disclosure requirements set...

Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026. ...

Oslo, 25 March 2026 - Observe Medical ASA (the "Company" or "Observe Medical") announces that its journey into the strategically important Indian market has reached a new level through the signing of an exclusive distribution agreement with a leading local partner. This replaces the previously announced LOI. The partner is a historical distributor of UnoMeter™ and brings deep market knowledge, an established sales network, and strong relationships within the Indian healthcare sector. This agreement represents an important milestone in the Company's expansion strategy in India, one of...

Oslo, 25 March 2026.  With reference to today's webcast, please find enclosed the presentation. Key topics: · 80% growth in quarterly sales LTM · Commercial launch of UnoMeter™ Safeti Max · Extended product offering to our distributors, capitalizing on the UnoMeter brand position · Sales in 46 countries  · Current addressable market value grown from NOK ~670m to ~2.6bn A recording of the presentation is also available at:https://qcnl.tv/p/OLaQ0Xa8KdjTtD9W3cv0PQ For further information, please contact: Jørgen Mann, CEO Observe Medical Mobile: +45 408 67 558...

Oslo, Norway, 25 March 2026 – The Board of Directors of Lytix Biopharma AS (the “Company”) (Euronext Growth Oslo: LYTIX) hereby calls for the Annual General Meeting to be held at Sandakerveien 138, 0484 Oslo, Norway, on 14 April 2026 at 13:00 hours (CEST).   The agenda for the Annual General Meeting includes, among other items, approval of the Company's annual report for 2025, election of board members, approval of remuneration to the Board of Directors and the Nomination Committee, and a new board authorization to increase the share capital in connection with the Company's option...

Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2025. ...